Notice of Closed Meeting, 1315 [2020-00256]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 7 / Friday, January 10, 2020 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)—RFA–IP20–
003, Network of Modeling Centers To
Improve Evidence Base for Seasonal
and Pandemic Influenza Prevention
and Control; Amended Notice of
Meeting
Notice of Closed Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)—RFA–
IP20–003, Network of Modeling Centers
to Improve Evidence Base for Seasonal
and Pandemic Influenza Prevention and
Control; February 25–26, 2020, 10:00
a.m.–5:00 p.m., (EDT).
Teleconference, Centers for Disease
Control and Prevention, Room 1080, 8
Corporate Square Boulevard, Atlanta,
GA 30329–4027 which was published in
the Federal Register on November 25,
2019, Volume 84, Number 227, page
64897.
The meeting is being amended to
change the meeting date to February 25,
2020. The meeting is closed to the
public.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE, Mailstop US8–1,
Atlanta, Georgia 30329–4027; (404) 718–
8833; gca5@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
jbell on DSKJLSW7X2PROD with NOTICES
[FR Doc. 2020–00255 Filed 1–9–20; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)-DP20–001, Assessing
the Burden of Diabetes By Type in Children,
Adolescents and Young Adults (DiCAYA).
Date: March 11, 2020.
Time: 10:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341; Telephone: (770) 488–6511;
Email: kva5@cdc.gov.
The Director, Strategic Business Initiatives
Unit, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
BILLING CODE 4163–18–P
VerDate Sep<11>2014
16:39 Jan 09, 2020
[Docket No. CDC–2020–0002]
[FR Doc. 2020–00256 Filed 1–9–20; 8:45 am]
BILLING CODE 4163–18–P
Jkt 250001
PO 00000
Frm 00018
Fmt 4703
Sfmt 4703
1315
Advisory Committee on Immunization
Practices (ACIP); Notice of Meeting
and Request for Comment
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public, limited only by room seating.
The meeting room accommodates 216
for public seating. Room 245, adjacent
to the meeting room, will be available
once the meeting room reaches capacity,
providing up to 18 additional seats.
Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web; for
meeting registration and more
information on ACIP please visit the
ACIP website: https://www.cdc.gov/
vaccines/acip/.
DATES: The meeting will be held on
February 26, 2020, 8:00 a.m. to 5:00
p.m., EST, and February 27, 2020, 8:00
a.m. to 2:30 p.m. EST.
Written comments must be received
on or before February 28, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0002 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS A–27, Atlanta, GA 30329–4027,
Attn: February ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov. Written
public comments submitted by 72 hours
prior to the ACIP meeting will be
provided to ACIP members before the
meeting.
Meeting location: Centers for Disease
Control and Prevention, 1600 Clifton
SUMMARY:
E:\FR\FM\10JAN1.SGM
10JAN1
]]>Agencies
[Federal Register Volume 85, Number 7 (Friday, January 10, 2020)]
[Notices]
[Page 1315]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-00256]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel (SEP)-DP20-001, Assessing the
Burden of Diabetes By Type in Children, Adolescents and Young Adults
(DiCAYA).
Date: March 11, 2020.
Time: 10:00 a.m.-6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341; Telephone: (770) 488-6511; Email: [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-00256 Filed 1-9-20; 8:45 am]
BILLING CODE 4163-18-P
